메뉴 건너뛰기




Volumn 9, Issue 4, 2014, Pages 1375-1386

Parallel InVivo and InVitro Melanoma RNAi Dropout Screens Reveal Synthetic Lethality between Hypoxia and DNA Damage Response Inhibition

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; BEVACIZUMAB; DABRAFENIB; DNA DAMAGE RESPONSE KINASE; PHOSPHOTRANSFERASE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA;

EID: 84912082427     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.10.024     Document Type: Article
Times cited : (35)

References (45)
  • 6
    • 84870218588 scopus 로고    scopus 로고
    • DNA repair dysregulation from cancer driver to therapeutic target
    • Curtin N.J. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer 2012, 12:801-817.
    • (2012) Nat. Rev. Cancer , vol.12 , pp. 801-817
    • Curtin, N.J.1
  • 9
    • 84859428543 scopus 로고    scopus 로고
    • Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells
    • Ferrao P.T., Bukczynska E.P., Johnstone R.W., McArthur G.A. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene 2011, 31:1661-1672.
    • (2011) Oncogene , vol.31 , pp. 1661-1672
    • Ferrao, P.T.1    Bukczynska, E.P.2    Johnstone, R.W.3    McArthur, G.A.4
  • 12
    • 0142120661 scopus 로고    scopus 로고
    • Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin
    • Giatromanolaki A., Sivridis E., Kouskoukis C., Gatter K.C., Harris A.L., Koukourakis M.I. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res. 2003, 13:493-501.
    • (2003) Melanoma Res. , vol.13 , pp. 493-501
    • Giatromanolaki, A.1    Sivridis, E.2    Kouskoukis, C.3    Gatter, K.C.4    Harris, A.L.5    Koukourakis, M.I.6
  • 16
    • 84873819555 scopus 로고    scopus 로고
    • Which drug, and when, for patients with BRAF-mutant melanoma?
    • Jang S., Atkins M.B. Which drug, and when, for patients with BRAF-mutant melanoma?. Lancet Oncol. 2013, 14:e60-e69.
    • (2013) Lancet Oncol. , vol.14 , pp. e60-e69
    • Jang, S.1    Atkins, M.B.2
  • 17
    • 2442665663 scopus 로고    scopus 로고
    • Gleevec: prototype or outlier?
    • Kaelin W.G. Gleevec: prototype or outlier?. Sci. STKE 2004, 2004:pe12.
    • (2004) Sci. STKE , vol.2004 , pp. pe12
    • Kaelin, W.G.1
  • 18
    • 25444497278 scopus 로고    scopus 로고
    • The concept of synthetic lethality in the context of anticancer therapy
    • Kaelin W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 2005, 5:689-698.
    • (2005) Nat. Rev. Cancer , vol.5 , pp. 689-698
    • Kaelin, W.G.1
  • 21
    • 84655161946 scopus 로고    scopus 로고
    • HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
    • Keith B., Johnson R.S., Simon M.C. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2012, 12:9-22.
    • (2012) Nat. Rev. Cancer , vol.12 , pp. 9-22
    • Keith, B.1    Johnson, R.S.2    Simon, M.C.3
  • 23
    • 34447258682 scopus 로고    scopus 로고
    • Microenvironmental influences in melanoma progression
    • Lee J.T., Herlyn M. Microenvironmental influences in melanoma progression. J.Cell. Biochem. 2007, 101:862-872.
    • (2007) J.Cell. Biochem. , vol.101 , pp. 862-872
    • Lee, J.T.1    Herlyn, M.2
  • 24
    • 61449182121 scopus 로고    scopus 로고
    • Principles of cancer therapy: oncogene and non-oncogene addiction
    • Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
    • (2009) Cell , vol.136 , pp. 823-837
    • Luo, J.1    Solimini, N.L.2    Elledge, S.J.3
  • 25
    • 79651470785 scopus 로고    scopus 로고
    • Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
    • Ma C.X., Janetka J.W., Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol. Med. 2011, 17:88-96.
    • (2011) Trends Mol. Med. , vol.17 , pp. 88-96
    • Ma, C.X.1    Janetka, J.W.2    Piwnica-Worms, H.3
  • 26
    • 84859726248 scopus 로고    scopus 로고
    • Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
    • Ma C.X., Cai S., Li S., Ryan C.E., Guo Z., Schaiff W.T., Lin L., Hoog J., Goiffon R.J., Prat A., et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J.Clin. Invest. 2012, 122:1541-1552.
    • (2012) J.Clin. Invest. , vol.122 , pp. 1541-1552
    • Ma, C.X.1    Cai, S.2    Li, S.3    Ryan, C.E.4    Guo, Z.5    Schaiff, W.T.6    Lin, L.7    Hoog, J.8    Goiffon, R.J.9    Prat, A.10
  • 28
    • 70349536006 scopus 로고    scopus 로고
    • Invivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression
    • Meacham C.E., Ho E.E., Dubrovsky E., Gertler F.B., Hemann M.T. Invivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nat. Genet. 2009, 41:1133-1137.
    • (2009) Nat. Genet. , vol.41 , pp. 1133-1137
    • Meacham, C.E.1    Ho, E.E.2    Dubrovsky, E.3    Gertler, F.B.4    Hemann, M.T.5
  • 29
    • 77953770987 scopus 로고    scopus 로고
    • Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair
    • Morgan M.A., Parsels L.A., Zhao L., Parsels J.D., Davis M.A., Hassan M.C., Arumugarajah S., Hylander-Gans L., Morosini D., Simeone D.M., et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 2010, 70:4972-4981.
    • (2010) Cancer Res. , vol.70 , pp. 4972-4981
    • Morgan, M.A.1    Parsels, L.A.2    Zhao, L.3    Parsels, J.D.4    Davis, M.A.5    Hassan, M.C.6    Arumugarajah, S.7    Hylander-Gans, L.8    Morosini, D.9    Simeone, D.M.10
  • 31
    • 78650333871 scopus 로고    scopus 로고
    • Targeting hypoxic cells through the DNA damage response
    • Olcina M., Lecane P.S., Hammond E.M. Targeting hypoxic cells through the DNA damage response. Clin. Cancer Res. 2010, 16:5624-5629.
    • (2010) Clin. Cancer Res. , vol.16 , pp. 5624-5629
    • Olcina, M.1    Lecane, P.S.2    Hammond, E.M.3
  • 33
    • 33745303045 scopus 로고    scopus 로고
    • Hypoxia signalling in cancer and approaches to enforce tumour regression
    • Pouysségur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437-443.
    • (2006) Nature , vol.441 , pp. 437-443
    • Pouysségur, J.1    Dayan, F.2    Mazure, N.M.3
  • 35
    • 78249250559 scopus 로고    scopus 로고
    • Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized
    • Quintana E., Shackleton M., Foster H.R., Fullen D.R., Sabel M.S., Johnson T.M., Morrison S.J. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010, 18:510-523.
    • (2010) Cancer Cell , vol.18 , pp. 510-523
    • Quintana, E.1    Shackleton, M.2    Foster, H.R.3    Fullen, D.R.4    Sabel, M.S.5    Johnson, T.M.6    Morrison, S.J.7
  • 38
    • 33746427040 scopus 로고    scopus 로고
    • Making progress through molecular attacks on cancer
    • Sawyers C.L. Making progress through molecular attacks on cancer. Cold Spring Harb. Symp. Quant. Biol. 2005, 70:479-482.
    • (2005) Cold Spring Harb. Symp. Quant. Biol. , vol.70 , pp. 479-482
    • Sawyers, C.L.1
  • 41
    • 69449096005 scopus 로고    scopus 로고
    • Heterogeneity in cancer: cancer stem cells versus clonal evolution
    • Shackleton M., Quintana E., Fearon E.R., Morrison S.J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009, 138:822-829.
    • (2009) Cell , vol.138 , pp. 822-829
    • Shackleton, M.1    Quintana, E.2    Fearon, E.R.3    Morrison, S.J.4
  • 42
    • 77954217479 scopus 로고    scopus 로고
    • Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock"
    • Sharma S.V., Settleman J. Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock". Biochem. Pharmacol. 2010, 80:666-673.
    • (2010) Biochem. Pharmacol. , vol.80 , pp. 666-673
    • Sharma, S.V.1    Settleman, J.2
  • 44
    • 33751301357 scopus 로고    scopus 로고
    • Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases
    • Syljuåsen R.G., Jensen S., Bartek J., Lukas J. Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases. Cancer Res. 2006, 66:10253-10257.
    • (2006) Cancer Res. , vol.66 , pp. 10253-10257
    • Syljuåsen, R.G.1    Jensen, S.2    Bartek, J.3    Lukas, J.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.